• Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations so far, and outlined plans to start a rolling FDA New Drug Application in the first quarter of 2027 and complete it by the third quarter of 2027.
• This smoother-than-expected enrollment, together with the clean retention profile, may strengthen confidence in the trial’s execution as the company approaches key regulatory milestones for its lead program.
• We’ll now examine how exceeding enrollment targets without patient discontinuations in the pivotal EMPEROR trial could influence Stoke Therapeutics’ investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics, you need to believe zorevunersen can become a meaningful treatment option in Dravet syndrome and eventually support a path toward stronger revenue and narrower losses. The EMPEROR trial exceeding enrollment with no discontinuations so far looks supportive for that near term catalyst, while the biggest current risk remains whether the full Phase III data will confirm the seizure and cognitive benefits seen in earlier, smaller studies.

Among recent announcements, the company’s June 30 update on EMPEROR is most relevant here, since it tied the enrollment progress directly to an expected rolling FDA NDA starting in the first quarter of 2027 and completing in the third quarter of 2027. That timeline, paired with Stoke’s ongoing losses (US$61.62 million net loss in Q2 2026), keeps the trial’s outcome and regulatory path firmly at the center of the stock’s near term risk and catalyst profile.

Yet behind the strong enrollment story, investors should also be aware of the longer term safety questions that could...

Stoke Therapeutics' narrative projects $177.8 million revenue and $33.6 million earnings by 2029. This requires 77.0% yearly revenue growth and a $203.4 million earnings increase from -$169.8 million today.

Uncover how Stoke Therapeutics' forecasts yield a $45.10 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue might grow about 103% annually to around US$267.0 million by 2029, but this EMPEROR update could either support that faster growth view or pull expectations closer to the more cautious narrative you saw earlier, reminding you that reasonable people can look at the same data and reach very different conclusions.

Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth just $35.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.